Influence of cellular immunity and pulmonary function status of budesonide combined with azithromycin sequential therapy in the treatment of mycoplasma pneumonia in children
CAO Shiyan;Department of Pediatrics, Changhai Hospital, Second Military Medical University;
Objective To research the influence of cellular immunity and pulmonary function status of budesonide combined with zaithromycin sequential therapy in the treatment of mycoplasma pneumonia in children. Methods 164 mycoplasma pneumonia cases in our hospital from August 2015 to October 2016 were selected as objects, which were divided into control group(n=84) and research group(n=80) randomly, the patients of control group were treated by zaithromycin sequential therapy, while the patients of research group were treated by budesonide combined with zaithromycin sequential therapy, the clinical efficacy, cellular immunity and pulmonary function of patients in two groups were compared. Results The effective rate of research group was 96.43%, which was much higher than control group(77.50%). The cellular immunity and pulmonary function after treatment of research group were much better than control group,and the difference was statistically significant(P 0.05). There was no statistically significant difference between the rate of adverse reaction in two groups(P 0.05). Conclusion Budesonide combined azithromycin sequential therapy can improve the clinical curative effect, improve the patient's level of cytokines, improve lung function in children with mycoplasma pneumonia and have better safety, and worth clinical promotion.
【CateGory Index】： R725.6